Last reviewed · How we verify
Transamine
Transamine is a Small molecule drug developed by Ankara Etlik City Hospital. It is currently in Phase 2 development. Also known as: tranexamic acid.
Transamine is a small molecule inhibitor of plasminogen, classified as an INHIBITOR drug class. It has been studied in various clinical trials for conditions such as panic disorder, blood loss, and congenital heart disease, among others.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Transamine |
|---|---|
| Also known as | tranexamic acid |
| Sponsor | Ankara Etlik City Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon Satisfaction (NA)
- Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery (PHASE4)
- Comparison of the Efficacy of Misoprostol and Tranexamic Acid for Postpartum Hemorrhage Prophylaxis in Cesarean Delivery
- Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
- MAO-B Occupancy in Depressed Patients (NA)
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Tranexamic Acid in Sleeve Gastrectomy (NA)
- Kaolin-based Hemostatic Gauze in Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transamine CI brief — competitive landscape report
- Transamine updates RSS · CI watch RSS
- Ankara Etlik City Hospital portfolio CI
Frequently asked questions about Transamine
What is Transamine?
Who makes Transamine?
Is Transamine also known as anything else?
What development phase is Transamine in?
Related
- Manufacturer: Ankara Etlik City Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: tranexamic acid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing